Literature DB >> 11728857

Dexamethasone suppression test and suicide attempts in schizophrenic patients.

M Płocka-Lewandowska1, A Araszkiewicz, J K Rybakowski.   

Abstract

The suicide attempts were assessed in 32 schizophrenic patients on whom the dexamethasone suppression test (DST) was done twice in the course of illness: in the years 1985-91 and 1996-97. In the 1985-91 period, both baseline and post-dexamethasone cortisol levels were significantly higher in the patients with previous suicide attempts and baseline cortisol was higher in the patients who were to make a future attempt. In 1996-97, DST non-suppression was shown in more than half of the patients with a history of suicide attempt and in none of those without such history: all cortisol levels were significantly higher in the patients with a history of suicide attempt. Although the mean intensity of depression was higher in the patients with a history of suicide attempt, no association between the intensity of depression and present or previous DST non-suppression status was found. It is suggested that the hyperactivity of the hypothalamic-pituitary-adrenal axis may constitute an element of diathesis for suicidal behavior in schizophrenic patients.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11728857     DOI: 10.1016/s0924-9338(01)00602-2

Source DB:  PubMed          Journal:  Eur Psychiatry        ISSN: 0924-9338            Impact factor:   5.361


  7 in total

1.  Abnormal glucocorticoid receptor mRNA and protein isoform expression in the prefrontal cortex in psychiatric illness.

Authors:  Duncan Sinclair; Shan Yuan Tsai; Heng Giap Woon; Cynthia Shannon Weickert
Journal:  Neuropsychopharmacology       Date:  2011-08-31       Impact factor: 7.853

Review 2.  Endophenotypes as a measure of suicidality.

Authors:  Dimitry A Chistiakov; Zurab I Kekelidze; Vladimir P Chekhonin
Journal:  J Appl Genet       Date:  2012-09-02       Impact factor: 3.240

3.  Dysregulation of the sympathetic nervous system, hypothalamic-pituitary-adrenal axis and executive function in individuals at risk for suicide.

Authors:  Alexander McGirr; Gabriel Diaconu; Marcelo T Berlim; Jens C Pruessner; Rebecca Sablé; Sophie Cabot; Gustavo Turecki
Journal:  J Psychiatry Neurosci       Date:  2010-11       Impact factor: 6.186

4.  A randomised controlled study of risperidone and olanzapine for schizophrenic patients with neuroleptic-induced acute dystonia or parkinsonism.

Authors:  H Y Chan; C J Chang; S C Chiang; J J Chen; C H Chen; H J Sun; H G Hwu; M S Lai
Journal:  J Psychopharmacol       Date:  2008-09-18       Impact factor: 4.153

5.  Suicide risk in schizophrenia: learning from the past to change the future.

Authors:  Maurizio Pompili; Xavier F Amador; Paolo Girardi; Jill Harkavy-Friedman; Martin Harrow; Kalman Kaplan; Michael Krausz; David Lester; Herbert Y Meltzer; Jiri Modestin; Lori P Montross; Preben Bo Mortensen; Povl Munk-Jørgensen; Jimmi Nielsen; Merete Nordentoft; Pirjo Irmeli Saarinen; Sidney Zisook; Scott T Wilson; Roberto Tatarelli
Journal:  Ann Gen Psychiatry       Date:  2007-03-16       Impact factor: 3.455

Review 6.  A new nosology of psychosis and the pharmacological basis of affective and negative symptom dimensions in schizophrenia.

Authors:  Costa Vakalopoulos
Journal:  Ment Illn       Date:  2010-05-06

7.  Increased Levels of Cortisol in Individuals With Suicide Attempt and Its Relation With the Number of Suicide Attempts and Depression.

Authors:  Alma Delia Genis-Mendoza; Diana María Dionisio-García; Thelma Beatriz Gonzalez-Castro; Carlos Alfonso Tovilla-Zaráte; Isela Esther Juárez-Rojop; María Lilia López-Narváez; Rosa Giannina Castillo-Avila; Humberto Nicolini
Journal:  Front Psychiatry       Date:  2022-06-10       Impact factor: 5.435

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.